消息面上，据广东药监消息，近日，国家药监局批准了香港位元堂药厂有限公司申报的猴枣除痰散上 市。这是首个通过简化港澳已上市传统口服中成药注册审批政策获批内地上市品种，标志着该项政策正 式落地见效。据位元堂年报披露，公司的三大旗舰产品包括"安宫牛黄丸"系列，金装安宫牛黄丸及药典 方安宫牛黄丸；经典的"养阴丸"，荣获广东省岭南中药文化遗产；以及连续十年销售冠军的"猴枣除痰 散"。 位元堂(00897)涨超11%，截至发稿，涨11.36%，报0.49港元，成交额253.02万港元。 ...

Core Viewpoint - The approval of the "Monkey's Paw Phlegm-Removing Powder" for mainland market entry marks a significant milestone for the company, reflecting the effectiveness of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bit Yuan Tang (00897), rose over 11%, reaching a price of 0.49 HKD with a trading volume of 2.53 million HKD [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey's Paw Phlegm-Removing Powder," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval of the product is the first instance of a traditional Chinese medicine being granted entry into the mainland market under the new simplified registration policy, indicating a positive trend for the industry [1]